{rfName}
Ph

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Rodriguez-Artalejo FAuthor

Share

September 1, 2022
Publications
>
Review

Pharmacological treatment of COVID-19: an opinion paper

Publicated to:Revista Espanola de Quimioterapia. 35 (2): 115-130 - 2022-04-01 35(2), DOI: 10.37201/req/158.2021

Authors: Garcia-Lledo, A; Gomez-Pavon, J; Gonzalez del Castillo, J; Hernandez-Sampelayo, T; Martin-Delgado, M C; Martin Sanchez, F J; Martinez-Selles, M; Molero Garcia, J M; Moreno Guillen, S; Rodriguez-Artalejo, F J; Ruiz-Galiana, J; Canton, R; De Lucas Ramos, P; Garcia-Botella, A; Bouza, E

Affiliations

Alfonso X El Sabio Univ, Cent Hosp Red Cross, Geriatr Serv, Madrid, Spain - Author
Autonomous Univ, Dept Publ Hlth, Madrid, Spain - Author
Cardiology Service. Gregorio Marañón General University Hospital, European University., Madrid, Spain - Author
Cardiology Service. Prince of Asturias Hospital, University of Alcalá, Madrid, Spain - Author
Clinical Emeritus, Community of Madrid, Clinical Microbiology and Infectious Diseases Service of the Gregorio Marañón General University Hospital, Complutense University. CIBERES. Cyber of Respiratory Diseases, Madrid, Spain - Author
Department of Public Health, Autonomous University, Madrid, Spain - Author
Emergency Service, San Carlos University Clinical Hospital, Complutense University, Madrid, Spain - Author
Emeritus. Pneumology Service, Gregorio Marañón General University Hospital, Complutense University, Madrid, Spain - Author
European Univ, Gregorio Maranon Gen Univ Hosp, Cardiol Serv, Madrid, Spain - Author
Family Medicine, Infectious diseases, Madrid, Spain - Author
Francisco Vitoria Univ, Torrejon Univ Hosp, Intens Med Serv, Madrid, Spain - Author
General Surgery Service, San Carlos University Clinical Hospital, Complutense University, Madrid, Spain - Author
Geriatrics Service. Central Hospital of the Red-Cross, Alfonso X el Sabio University, Madrid, Spain - Author
Geriatrics Service. San Carlos University Clinical Hospital. Complutense University, Madrid, Spain - Author
Infect Dis, Family Med, Madrid, Spain - Author
Infectious Diseases Service. Ramón y Cajal Hospital. University of Alcalá de Henares, Madrid, Spain - Author
Intensive Medicine Service, Torrejón University Hospital, Francisco de Vitoria University, Madrid, Spain - Author
Internal Medicine Service. Ruber International Hospital, Madrid, Spain - Author
Microbiology Service. Ramón y Cajal Hospital and Ramón y Cajal Institute for Health Research (IRYCIS), Spanish Network for Research in Infectious Pathology (REIPI), Madrid, Spain - Author
Pediatrics and ACES Service. Gregorio Marañón General University Hospital, Complutense University, Madrid, Spain - Author
Ramon & Cajal Hosp, Microbiol Serv, Madrid, Spain - Author
Ramon y Cajal Inst Hlth Res IRYCIS, Spanish Network Res Infect Pathol REIPI, Madrid, Spain - Author
Ruber Int Hosp, Internal Med Serv, Madrid, Spain - Author
Univ Alcala Henares, Ramon Y Cajal Hosp, Infect Dis Serv, Madrid, Spain - Author
Univ Alcala, Prince Asturias Hosp, Cardiol Serv, Madrid, Spain - Author
Univ Complutense Madrid, Gregorio Maranon Gen Univ Hosp, Clin Microbiol & Infect Dis Serv, Community Madrid, Madrid, Spain - Author
Univ Complutense Madrid, Gregorio Maranon Gen Univ Hosp, Pediat & ACES Serv, Madrid, Spain - Author
Univ Complutense Madrid, Gregorio Maranon Gen Univ Hosp, Pneumol Serv, Madrid, Spain - Author
Univ Complutense Madrid, San Carlos Univ Clin Hosp, Emergency Serv, Madrid, Spain - Author
Univ Complutense Madrid, San Carlos Univ Clin Hosp, Gen Surg Serv, Madrid, Spain - Author
Univ Complutense Madrid, San Carlos Univ Clin Hosp, Geriatr Serv, Madrid, Spain - Author
See more

Abstract

The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among ex-isting drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation. © 2022, Sociedad Espanola de Quiminoterapia. All rights reserved.

Keywords

19adalimumabanakinraazd7442azithromycinbanlanivimabbaricitinibblockadebrii-196brii-198canakinumabcasirivimabcertolizumabciganilmabcolchicineconvalescent plasmacorticosteroidscov2covid-19dexamethasoneetanerceptetesevimabevusheldfavipiravirfluvoxaminegolimumabhydroxychloroquineimdevinabinfliximabitolizumabivermectinlemilumablopinavir/ ritonavirlopinavir/ritonavirmetforminmoderatemolnupiravirpaxlovidpf-07321332ravulizumabremdesivirruxolitinibsarilumabsarssars-cov-2sotrovimabtixagevimabtocilizumabtofacitinibtreatmenttrialvitamin dAdalimumabAmubarvimabAnakinraAnti-sars-cov-2 agentAntiviral agentsAntivirus agentAzd7442AzithromycinBamlanivimabBanlanivimabBaricitinibBrii-196Brii-198Canakinu-mabCasirivimabCertolizumabCertolizumab pegolChild healthCiganilmabCilgavimabCilgavimab plus tixagevimabClinical effectivenessColchicineConvalescent plasmaCoronavirus disease 2019CorticosteroidCorticosteroidsCovidCovid-19DexamethasoneDrug efficacyDrug therapyEtanerceptEtesevimabEvusheldFavipiravirFluvoxamineGolimumabHumanHumansHydroxychloroquineImdevimabImdevinabImmune responseImmunoglobulinImmunomodulationInfliximabItolizumabIvermectinLe-milumabLopinavir plus ritonavirLopinavir/ritonavirMetforminMolnupiravirMonotherapyNonhumanOpen-labelPandemicPandemicsPaxlovidPf 07321332Pf-07321332Pregnant womanRavulizumabRemdesivirReviewRomlusevimabRuxolitinibSarilumabSars-cov-2Sars-cov2Severe acute respiratory syndrome coronavirus 2Sotrovi-mabSotrovimabSpainTixagevimabTocilizumabTofacitinibTreatmentTreatment outcomeTreatment planningVitamin d

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Revista Espanola de Quimioterapia, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Pharmacology & Pharmacy, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 8.87. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 8.64 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 9.31 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 37
  • Scopus: 38

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 131.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 142 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 12.75.
  • The number of mentions on the social network X (formerly Twitter): 6 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Additionally, the work has been submitted to a journal classified as Diamond in relation to this type of editorial policy.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/714550